Miraculins Announces Shares for Debt Settlement
December 29, 2014 (Source: Miraculins) — Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has entered into a shares for debt agreement with an officer of the Company and a member of the senior management team pursuant to which, and subject to regulatory approval, Miraculins will issue 133,660 of its common shares to said individuals at a deemed price of $0.245 per common share to satisfy $32,746.70 of outstanding amounts owing to them.
All of the shares to be issued will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
Get our daily investorintel update
For more information, please contact:
Christopher J. Moreau
President & CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of theTSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.